| [1] |
Wang CX, Pusic I, Anadkat MJ. Association of leukemia cutis with survival in acute myeloid leukemia[J].JAMA Dermatol,2019,155(7): 826-832. DOI:10.1001/jamadermatol.2019.0052. pmid:30969325 |
| [2] |
Martínez-Leboráns L, Victoria-Martínez AM, Torregrosa-Calatayud JL, et al. Leukemia cutis: a report of 17 cases and a review of the literature[J].Actas Dermosifiliogr,2016,107(9): e65-e69. DOI:10.1016/j.ad.2016.02.015. |
| [3] |
Sandre M, Osmond A, Ghazarian D, et al. Bullous leukemia cutis: a rare clinical subtype[J].Dermatol Online J,2019,25(6): 13030. DOI:10.5070/D3256044494. |
| [4] |
Aldapt MB, Yassin M. Leukemia cutis as an early presentation or relapsing manifestation of chronic lymphocytic leukemia (CLL)[J].Acta Biomed,2021,92(2): e2021192. DOI:10.23750/abm.v92i2. 10763. |
| [5] |
Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis[J].Ann Hematol,2002,81(2): 90-95. DOI:10.1007/s00277-001-0412-9. pmid:11907789 |
| [6] |
Robak E, Braun M, Robak T. Leukemia cutis-the current view on pathogenesis, diagnosis, and treatment[J].Cancers (Basel),2023,15(22): 5393. DOI:10.3390/cancers15225393. |
| [7] |
Cho-Vega JH, Medeiros LJ, Prieto VG, et al. Leukemia cutis[J].Am J Clin Pathol,2008,129(1): 130-142. DOI:10.1309/WYACYWF6NGM3WBRT. pmid:18089498 |
| [8] |
Bystrom R, Levis MJ. An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape[J].Curr Oncol Rep,2023,25(4): 369-378. DOI:10.1007/s11912-023-01389-2. |
| [9] |
Wang ES, Goldberg AD, Tallman M, et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML[J].J Clin Oncol,2024,42(15): 1776-1787. DOI:10.1200/JCO.23. 01061. |
| [10] |
Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence[J].Leukemia,2019,33(2): 299-312. DOI:10.1038/s41375-018-0357-9. pmid:30651634 |
| [11] |
Antar AI, Otrock ZK, Jabbour E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions[J].Leukemia,2020,34(3): 682-696. DOI:10.1038/s41375-019-0694-3. pmid:31919472 |
| [12] |
Grafone T, Palmisano M, Nicci C, et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment[J].Oncol Rev,2012,6(1): e8. DOI:10.4081/oncol.2012.e8. |
| [13] |
陈曦, 母丹, 严钦, 等. 骨髓微环境与白血病细胞分化[J].国际肿瘤学杂志,2021,48(3): 189-192. DOI:10.3760/cma.j.cn371439- 20200619-00038. |
| [14] |
Song MK, Park BB, Uhm JE. Clinical efficacies of FLT3 inhibitors in patients with acute myeloid leukemia[J].Int J Mol Sci,2022,23(20): 12708. DOI:10.3390/ijms232012708. |
| [15] |
Karagounis TK, Rotemberg V, Geskin LJ, et al. NPM1 and FLT3-TKD mutations are enriched in patients with leukemia cutis[J].Dermatol Online J,2020,26(7): 13030/qt5gc4c36x. DOI:10. 5070/D3267049552. |
| [16] |
Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, et al. FLT3 mutations in myeloid sarcoma[J].Br J Haematol,2004,126(6): 785-791. DOI:10.1111/j.1365-2141.2004.05124.x. |